Humanigen

OverviewSuggest Edit

Humanigen (formerly known as KaloBios) is repositioning and developing its proprietary monoclonal antibodies to meet some critical unmet needs in cancer science. The Company's focus is on making chimeric antigen receptor T-cell (CAR-T) therapy safer, better and more routine. Its lead asset lenzilumab is poised to begin testing for possible prophylaxis of neurotoxicity and cytokine release syndrome related to CAR-T treatment.

TypePublic
Founded2000
HQBurlingame, CA, USMap
Websitehumanigen.com

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)2(-33%)
Revenue (FY, 2020)$312 K
Share Price (Oct 2021)$6.4
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Humanigen

Cameron Durrant

Cameron Durrant

Chairman & CEO
Bob Atwill

Bob Atwill

SVP, Head of Asia-Pacific Region
Ken Trbovich

Ken Trbovich

SVP, Investor Relations
Dale Chappell

Dale Chappell

Chief Scientific Officer
Edward P. Jordan

Edward P. Jordan

Chief Commercial Officer
Omar Ahmed

Omar Ahmed

SVP. Clinical, Medical and Scientific Affairs
Show more

Humanigen Office Locations

Humanigen has offices in Burlingame and Kansas City
Burlingame, CA, US (HQ)
533 Airport Blvd #400
Kansas City, MO, US
900 W 48th Pl #900, Kansas City
Show all (2)

Humanigen Financials and Metrics

Humanigen Revenue

Humanigen's revenue was reported to be $312 k in FY, 2020
USD

Revenue (FY, 2020)

312.0k

Net income (FY, 2020)

(89.5m)

EBIT (FY, 2020)

(88.2m)

Market capitalization (15-Oct-2021)

379.9m

Closing stock price (15-Oct-2021)

6.4

Cash (31-Dec-2020)

67.7m
Humanigen's current market capitalization is $379.9 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

312.0k

General and administrative expense

14.3m8.4m7.9m9.1m6.3m15.8m

R&D expense

16.7m10.4m11.2m2.2m2.6m72.7m

Operating expense total

34.4m18.8m19.0m11.3m8.9m88.5m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

General and administrative expense

1.2m2.5m2.5m2.4m1.5m2.0m4.0m2.0m1.8m1.9m1.7m1.5m1.4m2.0m

R&D expense

1.7m4.4m1.7m2.7m3.9m3.8m696.0k577.0k535.0k359.0k1.2m549.0k659.0k21.1m

Operating expense total

2.9m6.9m4.2m5.1m5.4m5.8m4.7m2.6m2.3m2.2m3.0m2.0m2.1m23.1m

EBIT

(2.9m)(6.9m)(4.2m)(5.1m)(5.4m)(5.8m)(4.7m)(2.6m)(2.3m)(2.2m)(3.0m)(2.0m)(2.1m)(23.1m)
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

8.4m2.9m737.0k814.0k143.0k67.7m

Prepaid Expenses

2.0m1.6m813.0k485.0k309.0k475.0k

Current Assets

10.4m4.5m1.6m1.3m452.0k68.2m

PP&E

288.0k68.0k19.0k
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

6.6m11.9m2.9m4.0m103.0k1.1m1.6m267.0k2.0m180.0k1.1m157.0k68.0k41.7m

Prepaid Expenses

1.7m1.3m1.8m1.7m1.5m1.2m838.0k665.0k504.0k479.0k425.0k366.0k293.0k770.0k

Current Assets

8.3m13.3m4.7m5.7m1.7m2.3m2.4m932.0k2.5m659.0k1.5m523.0k361.0k42.5m

PP&E

170.0k145.0k121.0k53.0k41.0k30.0k10.0k
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(35.4m)(27.0m)(22.0m)(12.0m)(10.3m)(89.5m)

Depreciation and Amortization

197.0k102.0k48.0k19.0k

Accounts Payable

2.5m4.5m(520.0k)(198.0k)2.2m8.0m

Cash From Operating Activities

(29.1m)(21.0m)(14.2m)(6.2m)(4.0m)(69.9m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(5.4m)(17.4m)(22.0m)(5.5m)(11.7m)(18.9m)(5.1m)(7.8m)(9.9m)(2.5m)(5.9m)(8.3m)(2.5m)(26.5m)

Depreciation and Amortization

33.0k58.0k81.0k14.0k27.0k38.0k10.0k19.0k19.0k

Accounts Payable

3.2m4.6m3.5m(507.0k)(434.0k)327.0k(28.0k)(88.0k)(159.0k)592.0k717.0k1.1m860.0k(2.9m)

Cash From Operating Activities

(2.0m)(9.0m)(17.9m)(4.4m)(8.3m)(12.3m)(1.8m)(3.7m)(5.0m)(684.0k)(2.3m)(3.5m)(607.0k)(22.6m)
show all
USDFY, 2015

Financial Leverage

1.9 x
Show all financial metrics

Humanigen Operating Metrics

FY, 2015FY, 2016FY, 2017

Patent Applications

692617

Patents (Foreign)

376442

Patents (US)

72318
Show all operating metrics

Humanigen Acquisitions / Subsidiaries

Company NameDateDeal Size
Celscia Therapeutics
KaloBios

Humanigen Online and Social Media Presence

Humanigen's Trends

Embed Graph

Humanigen News and Updates

September 10, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humanigen, Inc. - HGEN

NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Humanigen, Inc. ("Humanigen" or the "Company") (NASDAQ: HGEN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The...
September 09, 2021

Thinking about buying stock in Globalstar, Pharmacyte Biotech, Humanigen, Kadmon Holdings, or Camber Energy?

NEW YORK, Sept. 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GSAT, PMCB, HGEN, KDMN, and CEI. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
March 12, 2021

Thinking about buying stock in Palantir Technologies, Super League Gaming, Phunware, Humanigen, or BioXcel Therapeutics?

New York, March 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PLTR, SLGG, PHUN, HGEN, and BTAI. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding...
February 03, 2021

Humanigen and Avid Bioservices Enter into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing

BURLINGAME, Calif. and TUSTIN, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”) today announced that they have entered into a manufacturing services agreement to expand production capacity for len…
January 25, 2021

Humanigen signs manufacturing deal with Emergent for experimental COVID-19 drug

Shares of Humanigen Inc. were down 2.5% in trading on Monday after it announced a contract development and manufacturing deal with Emergent BioSolutions Inc. for its experimental COVID-19 treatment. Emergent's stock was down 1.7%. The investigational therapy, lenzilumab, is currently being tested …
May 31, 2019

Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (axicabtagene ciloleucel) With lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

-- Phase 1/2 Multi-Center Clinical Trial to Begin Enrolling in Q4 2019 -- -- Phase 1/2 Multi-Center Clinical Trial to Begin Enrolling in Q4 2019 --
Show more

 Humanigen Frequently Asked Questions

  • When was Humanigen founded?

    Humanigen was founded in 2000.

  • Who are Humanigen key executives?

    Humanigen's key executives are Cameron Durrant, Bob Atwill and Ken Trbovich.

  • How many employees does Humanigen have?

    Humanigen has 2 employees.

  • What is Humanigen revenue?

    Latest Humanigen annual revenue is $312 k.

  • What is Humanigen revenue per employee?

    Latest Humanigen revenue per employee is $156 k.

  • Who are Humanigen competitors?

    Competitors of Humanigen include Abcam, XOMA and MiracleCord.

  • Where is Humanigen headquarters?

    Humanigen headquarters is located at 533 Airport Blvd #400, Burlingame.

  • Where are Humanigen offices?

    Humanigen has offices in Burlingame and Kansas City.

  • How many offices does Humanigen have?

    Humanigen has 2 offices.